Tech Company Financing Transactions
Biscayne Therapeutics Funding Round
Biscayne Therapeutics closed a $3 million Series B funding round on 1/30/2017. Investors included Mesa Verde Venture Partners and Quark Venture.
Transaction Overview
Company Name
Announced On
1/30/2017
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to initiate and complete a Phase 1b proof of concept trial of its new extended release formulation of BIS-001 in 2017.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4770 Biscayne Blvd. 660
Miami, FL 33137
USA
Miami, FL 33137
USA
Phone
Website
Email Address
Overview
Biscayne Pharmaceuticals is developing novel drugs for cancer and other serious disorders based on analogs of growth hormone-releasing hormone (GHRH) discovered by Dr. Andrew V. Schally, Nobel laureate and renowned drug researcher.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Samuel Reich
Chief Executive Officer
Stephen Collins
VP - Finance
Jared Mendel
VP - R & D
Peter Goldstein
VP - R & D
Joshua Johnstone
Browse more venture capital transactions:
Prev: 1/30/2017: Chute venture capital transaction
Next: 1/30/2017: UberCloud venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs